2017 GLOBAL DIABETES MANAGEMENT DEVICES MARKET160 Pages | 42 Exhibits | 2017 Analysis | Forecasts Through 2020
DIABETES MANAGEMENT DEVICES MARKET HIGHLIGHTS
- The substantial and highly competitive global diabetes management devices market was valued at more than $9 billion in 2015 and is expected to grow at a healthy CAGR approaching 5%.
- The highest growth segment is insulin pump systems, expected to expand by a CAGR in the upper single-digits due to strong innovation, automatic insulin delivery, lucrative disposables, and strong demand
- The largest segment in terms of dollar volume in 2015 was blood glucose monitoring systems due to a broad range of products, large number of competitors, and strong usage by both type 1 and type 2 diabetics worldwide.
- Demographic trends leading to growth include: increased diabetes caseloads, positive clinical data, and strong technological innovation leading to the adoption of the first approved hybrid closed-loop artificial pancreas (by Medtronic). Additionally, the miniaturization and continued improvement of continuous glucose monitoring, the adoption of wireless, smartphone-driven diabetes management technologies, and the expected launch of several next-generation insulin delivery systems will further enhance growth.
- What is the value of the global diabetes management devices market and expected growth for leading device (glucose meters vs insulin pumps) segments?
- What is the expected market growth in various regions of the world (US, 5EU, Japan and RoW)?
- What are key market drivers & limiters?
- Which competitors are leading the market and introducing new technology? What is the estimated market share for each?
- How are technological advancements impacting market growth?
- Which areas of the market are lagging?
- What are competitor's growth strategies?
Publisher: Medtech Insight
EXECUTIVE SUMMARY i. Report overview ii. Diabetes prevalence iii. Global diabetes management devices market a. Selected market drivers and limiters b. Blood glucose monitoring devices segment c. Insulin pump systems segment d. Technology trends e. Market leaders f. Competitive strategies g. Emerging competition/startups iv. Methodology Exhibit ES-1: Diabetes management devices market forecast, by segment, 2015-20 Exhibit ES-2: Diabetes management devices market forecast, by region, 2015-20 Exhibit ES-3: Diabetes management devices market, estimated share by region, 2015 1. OVERVIEW OF DIABETES 1.1 Overview of Diabetes 1.1.1 Symptoms 1.1.2 Complications 1.1.3 Diagnosis and treatment/prevention 22.214.171.124 The importance of maintaining glucose control 126.96.36.199 Limitations of self-monitoring blood glucose 188.8.131.52 Insulin and usage of insulin pumps 1.2 Cost of Diabetes 1.3 Diabetes Prevalence 1.3.1 Diabetes forecast for the US, 5EU, and Japan 184.108.40.206 Type 1 diabetes forecast 220.127.116.11 Type 2 diabetes forecast 1.3.2 Prediabetes in the US 1.4 New Diabetes Device Technologies, Brief Overview 1.4.1 Continuous blood glucose monitoring and patch-based systems 1.4.2 The world's first external artificial pancreas device system 1.5 Bibliography Exhibit 1-1: Estimated diabetes prevalence, worldwide and by region, 2015 and 2040 Exhibit 1-2: Type 1 diabetes prevalence across the US, Japan, and five major EU markets, by country, 2015-20 Exhibit 1-3: Type 2 diabetes prevalence across the US, Japan, and five major EU markets, by country, 2015-20 Exhibit 1-4: Diagram of an artificial pancreas system (an autonomous system for glycemic control) by the FDA 2. GLUCOSE MONITORING DEVICES 2.1 Selected Blood Glucose Meters 2.1.1 Abbott Laboratories 2.1.2 Ascensia Diabetes Care/Panasonic Healthcare Holdings 2.1.3 LifeScan/Johnson & Johnson 2.1.4 Roche 2.2 Selected Continuous Glucose Monitoring Systems 2.2.1 Abbott Laboratories 2.2.2 Dexcom 18.104.22.168 Dexcom and Google/Verily Life Sciences 2.2.3 Medtronic 22.214.171.124 Medtronic/Qualcomm 126.96.36.199 Medtronic/IBM Watson Health 2.2.4 Nemaura Medical 2.2.5 Senseonics/Roche 2.3 Bibliography Exhibit 2-1: Blood glucose monitoring brands and portfolios offered by leading competitors, 2016 Exhibit 2-2: Selected new blood glucose monitoring devices, 2016 Exhibit 2-3: Ascensia's new Contour Next One and Contour Diabetes app Exhibit 2-4: LifeScan's new OneTouch Verio Flex Exhibit 2-5: Roche's Accu-Chek Mobile all-in-one system allowing "strip-free" testing Exhibit 2-6: Selected new continuous glucose monitoring devices/sensors, 2016 Exhibit 2-7: Abbott's FreeStyle Libre Pro reader device and sensor Exhibit 2-8: The Dexcom G5 Mobile CGM system Exhibit 2-9: Medtronic's Guardian Connect mobile CGM system Exhibit 2-10: Medtronic's Enlite Sensor used with the MiniMed 530G insulin pump Exhibit 2-11: Senseonics/Roche's new Eversense implantable CGM system 3. INSULIN PUMPS AND EMERGING INSULIN DELIVERY DEVICES 3.1 Selected Insulin Pumps 3.1.1 Animas/Johnson & Johnson 3.1.2 Insulet Corporation 3.1.3 Medtronic 3.1.4 Roche 3.1.5 Tandem Diabetes Care 3.2 Other Insulin Delivery Devices 3.2.1 Cellnovo 3.2.2 Calibra Medical/Johnson & Johnson 3.2.3 Valeritas 3.3 Bibliography Exhibit 3-1: Selected new or emerging insulin pump/delivery systems, 2016 Exhibit 3-2: OneTouch Ping and Animas Vibe insulin pump systems Exhibit 3-3: Omnipod and three-step insulin delivery Exhibit 3-4: Medtronic's New MiniMed 630G and 530G insulin pump systems Exhibit 3-5: Tandem Diabetes Care's t:slim G4 insulin pump Exhibit 3-6: The Cellnovo Diabetes Management System Exhibit 3-7: The V-Go Disposable and Wearable Insulin Delivery Device 4. ARTIFICIAL PANCREAS AND EMERGING/COMPETING TECHNOLOGIES 4.1 Medtronic's Artificial Pancreas - the MiniMed 670G 4.2 Artificial Pancreas Technology - Under Development 4.2.1 Beta Bionics 4.2.2 Bigfoot Biomedical 4.2.3 Cellnovo 4.2.4 Insulet Corporation 4.2.5 Tandem Diabetes Care/Dexcom/TypeZero 4.2.6 TypeZero Technologies 4.3 Bibliography Exhibit 4-1: Medtronic's MiniMed 670G, the first FDA-approved artificial pancreas Exhibit 4-2: Selected emerging artificial pancreas systems and expected launch, 2018-19 Exhibit 4-3: TypeZero's inControl proprietary smartphone-driven hybrid closed-loop AP algorithm and partnership collaboration Exhibit 4-4: TypeZero's inControl smartphone-driven artificial pancreas featuring inControl Advice 5. GLOBAL DIABETES MANAGEMENT DEVICES MARKET 5.1 Global Market Analysis 5.1.1 Market drivers and limiters 5.1.2 Market forecast: US 188.8.131.52 Reimbursement issues 184.108.40.206.1 Blood glucose monitors/testing supplies 220.127.116.11.2 Continuous glucose monitoring devices 18.104.22.168.3 Insulin pumps 5.1.3 Market forecast: 5EU 5.1.4 Market forecast: Japan 5.1.5 Market forecast: rest of the world 5.1.6 Competitive analysis: global 22.214.171.124 Global market share: diabetes management devices (total market) 126.96.36.199.1 Estimated global market share: blood glucose monitoring devices 188.8.131.52.2 Estimated global market share: insulin pump systems 184.108.40.206 Competitive analysis: US 220.127.116.11 Competitive analysis: EU 18.104.22.168 Competitive analysis: Japan 22.214.171.124 Competitive analysis: rest of the world 5.1.7 Detailed analysis, by competitor 126.96.36.199 Ascensia Diabetes Care (formerly Bayer Diabetes Care) 188.8.131.52.1 Strategic growth initiatives 184.108.40.206 Abbott Laboratories 220.127.116.11.1 Strategic growth initiatives 18.104.22.168 Johnson & Johnson 22.214.171.124.1 Strategic growth initiatives 126.96.36.199 Medtronic 188.8.131.52.1 Strategic growth initiatives 184.108.40.206 Roche 220.127.116.11.1 FY2015 18.104.22.168.2 FY2016 22.214.171.124.3 Strategic growth initiatives 126.96.36.199 Dexcom 188.8.131.52.1 FY2015 184.108.40.206.2 FY2016 220.127.116.11.3 Strategic growth initiatives 18.104.22.168 Insulet Corporation 22.214.171.124.1 FY2015 126.96.36.199.2 FY2016 188.8.131.52.3 Strategic growth initiatives 184.108.40.206 Tandem Diabetes Care 5.2 Bibliography Exhibit 5-1: Diabetes management devices market forecast, by segment and region, 2015-20 Exhibit 5-2: Global diabetes management devices market, estimated share by region, 2015 Exhibit 5-3: Global diabetes management devices market, estimated share by region, 2020 Exhibit 5-4: Global diabetes management devices market, estimated share by device segment, 2015 Exhibit 5-5: Global diabetes management devices market, estimated share by device segment, 2020 Exhibit 5-6: Selected market drivers and limiters for diabetes management devices Exhibit 5-7: Diabetes management devices global market, share by supplier, 2015 Exhibit 5-8: Blood glucose monitoring devices global market, share by supplier, 2015 Exhibit 5-9: Insulin pumps global market, share by supplier, 2015 Exhibit 5-10: Diabetes management devices US market, share by supplier, 2015 Exhibit 5-11: Diabetes management devices 5EU market, share by supplier, 2015 Exhibit 5-12: Diabetes management devices Japan market, share by supplier, 2015 Exhibit 5-13: Diabetes management devices RoW market, share by supplier, 2015 APPENDIX A: COMPANY LISTING
- Abbott Laboratories
- Animas Corporation
- Arkray USA
- Ascensia Diabetes Care Holdings AG
- Beta Bionics
- Bigfoot Biomedical
- Bionime USA Corporation
- Cellnovo Group
- Dexcom, Inc.
- F. Hoffman-LaRoche, Ltd. (Roche)
- IBM Watson Health
- iHealth Labs, Inc.
- Insulet Corporation
- LifeScan/Johnson & Johnson
- Medtronic plc
- Nemaura Medical
- Nova Biomedical/Nova Diabetes Care plc
- Panasonic Healthcare Co., Ltd.
- Prodigy Diabetes Care, LLC
- Tandem Diabetes Care
- Trividia Health
- TypeZero Technologies, LLC
- Verily Life Sciences
A Single License allows for one person to access the report. A Corporate License allows for multiple individuals within a company to access the report.